The Interleukin-17 Family of Cytokines in Breast Cancer - Université de Reims Champagne-Ardenne Access content directly
Journal Articles International Journal of Molecular Sciences Year : 2018

The Interleukin-17 Family of Cytokines in Breast Cancer


Breast cancer (BC) is the most common cancer in women worldwide and remains a major cause of mortality with an expected 137,000 death this year in Europe. Standard management of metastatic BC comprises hormonotherapy, chemotherapy, and targeted therapies. Cyclin dependent kinase (CDK) and mammalian target of rapamycin (mTOR) inhibitors have recently proved their efficiency in hormonal receptor expressing BC. Checkpoint proteins inhibition is being evaluated in phase 3 studies. Since inflammation is constantly present in cancers, research teams have focused their attention on the interleukin-17 (IL-17) family of proinflammatory cytokines. Preclinical experiments have reported both pro and antitumor effects depending on the conditions. In the present article, we review the accumulating evidences about the roles of IL-17 in BC and discuss whether this family of cytokines could be a new target in anticancer treatments.
Fichier principal
Vignette du fichier
Fabre J 2018.pdf (1.27 Mo) Télécharger le fichier
Origin Publisher files allowed on an open archive

Dates and versions

hal-02278302 , version 1 (04-09-2019)



Joseph Antoine Salvator Fabre, Jérôme Giustinniani, Christian Garbar, Yacine Merrouche, Frank Antonicelli, et al.. The Interleukin-17 Family of Cytokines in Breast Cancer. International Journal of Molecular Sciences, 2018, 19 (12), pp.3880. ⟨10.3390/ijms19123880⟩. ⟨hal-02278302⟩
75 View
123 Download



Gmail Mastodon Facebook X LinkedIn More